Baycrest

Dr. Howard Chertkow joins Baycrest as the new Chair in Cognitive Neurology and Innovation and a Senior Scientist at the Rotman Research Institute. Along with those roles, Dr. Chertkow is Director of the new Kimel Family Centre for Brain Health and Wellness, a research, education, and clinical interdisciplinary program to develop and evaluate the most promising approaches to preventing cognitive decline in older adults. Dr. Chertkow is also assembling a state-of-the- art Clinical Trials Unit to further develop Baycrest's translational research program in dementia to test the latest emerging therapies for Alzheimer's disease and related conditions. As well, he is a Clinical Advisor to the Centre for Aging + Brain Health Innovation (CABHI), the largest venture of its kind in the global seniors' care sector. Dr. Chertkow is a remarkably distinguished cognitive neurologist whose contributions are admired across the world. In his previous role as Director of the Memory Clinic at the Jewish General Hospital/McGill University, he diagnosed and treated patients with early stage Alzheimer's disease and other dementias, and helped found and direct Canada's largest memory clinic. He is an exceptionally prolific researcher in the area of dementia, serving since 2014 as Scientific Director of the Canadian Consortium on Neurodegeneration in Aging (CCNA), which has brought together 400 leading dementia researchers across Canada, and a member of the national Ministerial Advisory Board on Dementia, co-chaired by Baycrest's President and CEO, Dr. William Reichman. With Dr. Chertkow's arrival, Baycrest has become the Headquarters and Research Network Centre for the CCNA, which complements the RRI's focus on the prevention, detection, and treatment of dementia. CAREER HIGHLIGHTS Awarded $40 million in research funding as a principal investigator Recipient of the first Canadian Institutes of Health Research Foundation grant in the domain of aging and geriatrics Past President of the Consortium of Canadian Centres for Clinical Cognitive Research, a group that played an important role in the development of dementia clinical trials in Canada Head of the team that developed the Montreal Cognitive Assessment (MoCA), an international standard for the diagnosis of mild cognitive impairment First to show that a type of brain stimulation – transcranial direct current stimulation – can produce clinically meaningful improvements in older adults with neurodegenerative diseases 2017–2018 YEAR IN REVIEW 21 Baycrest welcomes Canada's pre-eminent neurologist-scientist

• Cover